Publicaciones científicas

/cun/es_EC/investigacion/publicaciones-cientificas/areaMain/02
  • Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment

    Dimopoulos MA (1), Stewart AK (2), Masszi T (3), Špička I (4), Oriol A (5), Hájek R (6), Rosiñol L (7), Siegel D (8), Mihaylov GG (9), Goranova-Marinova V (10), Rajnics P (11), Suvorov A (12), Niesvizky R (13), Jakubowiak A (14), San-Miguel J (15), Ludwig H (16), Ro S (17), Aggarwal S (17), Moreau P (18), Palumbo A (19)

    (1) School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
    (2)Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ, USA.
    (3) Department of Hematology and Stem-Cell Transplantation, St. István and St. László Hospital, Semmelweis University, Budapest, Hungary.
    (4) Department of Internal Medicine, Charles University in Prague, First Faculty of Medicine and General Teaching Hospital, Prague, Czech Republic.
    (5) Department of Clinical Hematology, Institut Català d'Oncologia-Hospital Universitari Germans Trias i Pujol, Institut Josep Carreras, Barcelona, Spain.
    (6) Faculty of Medicine, University Hospital Ostrava, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
    (7) Department of Hematology, Hospital Clínic de Barcelona, Barcelona, Spain.
    (8) Division of Multiple Myeloma, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA.
    (9) Hematological Clinic, Queen Joanna University Hospital, Sofia, Bulgaria.
    (10) Hematology Clinic, University Multiprofile Hospital for Active Treatment 'Sv. Georgi' and Medical University, Plovdiv, Bulgaria.
    (11) Department of Hematology, Mór Kaposi Teaching Hospital, Kaposvár, Hungary.
    (12) First Republican Clinical Hospital of Udmurtia, Izhevsk, Russia.
    (13) Multiple Myeloma Center, Weill Cornell Medical College, New York, NY, USA.
    (14)Myeloma Program, University of Chicago Medicine, Chicago, IL, USA.
    (15) Clinical and Translational Medicine, Clinica Universidad de Navarra-Centro de Investigación Médica Aplicada, IDISNA, CIBERONC, Pamplona, Spain.
    (16) Department of Medicine, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria.
    (17) Onyx Pharmaceuticals, Inc., An Amgen Subsidiary, South San Francisco, CA, USA.
    (18) Department of Hematology, University of Nantes, Nantes, France.
    (19) Myeloma Unit, Department of Oncology, University of Turin, Turin, Italy. 

    Blood Cancer 21 de ABRIL de 2017

  • Increased phagocytic NADPH oxidase activity associates with coronary artery calcification in asymptomatic men

    Beloqui O (1,2), Moreno MU (2,3), San José G (2,3), Pejenaute Á (4), Cortés A (4), Landecho MF (1,2), Díez J (2,5), Fortuño A (2,3), Zalba G (2,3,4).

    (1a) Department of Internal Medicine , Clínica Universidad de Navarra , Pamplona , Spain.
    (2b) IdiSNA, Navarra Institute, for Health Research Pamplona , Spain.
    (3c) Program of Cardiovascular Diseases, Centre for Applied Medical Research, University of Navarra , Pamplona , Spain.
    (4d) Department of Biochemistry and Genetics , University of Navarra , Pamplona , Spain.
    (5e) Deparment of Cardiology and Cardiac Surgery , Clínica Universidad de Navarra , Pamplona , Spain. 

    Free Radical Research 20 de ABRIL de 2017

  • Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040)

    Dr Anthony B El-Khoueiry, MD (a), Bruno Sangro, MD (b), †, Thomas Yau, MD (c), †, Todd S Crocenzi, MD (d), Masatoshi Kudo, MD (e), Chiun Hsu, MD (f), Tae-You Kim, MD (g), Su-Pin Choo, BMBS (h), Jörg Trojan, MD (i), Theodore H Welling 3rd, MD (j), Tim Meyer, MDk, Yoon-Koo Kang, MD (l), Winnie Yeo, MD (m), Akhil Chopra, MD (n), Jeffrey Anderson, MD (o), Christine dela Cruz, MD (o), Lixin Lang, PhD (o), Jaclyn Neely, PhD (o), Hao Tang, PhD (o), Homa B Dastani, PhD (o), Ignacio Melero (p, q)
    (a) USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA
    (b) Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain
    (c) University of Hong Kong, Hong Kong Special Administrative Region, China
    (d) Providence Cancer Center, Portland, OR, USA
    (e) Kindai University Faculty of Medicine, Osaka, Japan
    (f) National Taiwan University Hospital, Taipei, Taiwan
    (g) Seoul National University Hospital, Seoul, South Korea
    (h) National Cancer Center, Singapore
    (i) Goethe University Hospital and Cancer Center, Frankfurt, Germany
    (j) University of Michigan School of Medicine, Ann Arbor, MI, USA
    (k) Royal Free Hospital, London, UK
    (l) Asan Medical Center, University of Ulsan, Seoul, South Korea
    (m) Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
    (n) Johns Hopkins Singapore International Medical Centre, Singapore
    (o) Bristol-Myers Squibb, Princeton, NJ, USA
    (p) Biomedical Research Network in Oncology (CIBERONC), Pamplona, Spain
    (q) Center for Applied Medical Research (CIMA), Pamplona, Spain 

    The Lancet 20 de ABRIL de 2017

  • Durable complete remission with aromatase inhibitor therapy in a patient with metastatic uterine carcinosarcoma with poor performance status and coagulation disorders

    Martin-Romano P (1), Jurado M (2), Idoate MA (3), Arbea L (4), Hernandez-Lizoain JL (5), Cano D (6), Paramo JA (7), Martin-Algarra S (4).

    (1) Department of Oncology, Clínica Universidad de Navarra, Avenida Pío XII 36, 31008, Pamplona, Spain. pmromano@unav.es.
    (2) Department of Gynecology, Clínica Universidad de Navarra, Pamplona, Spain.
    3 Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain.
    (4) Department of Oncology, Clínica Universidad de Navarra, Avenida Pío XII 36, 31008, Pamplona, Spain.
    (5) Department of General Surgery, Clínica Universidad de Navarra, Pamplona, Spain.
    (6) Department of Radiology, Clínica Universidad de Navarra, Pamplona, Spain.
    (7) Hematology Service, Clínica Universidad de Navarra, Pamplona, Spain. 

    Journal of Medical Case Reports 19 de ABRIL de 2017

  • Telomere shortening and accelerated aging in COPD

    Elizabeth CL (1), Sara CR (2), Adriana EJ (2), de-Torres JP (3), María-José P (4), Armando AJ 2, Bartolomé C (5), Ciro C (2,6).
    (1) Research Unit, Hospital Universitario Nuestra Señora de Candelaria, Ctra. del Rosario 145, 38010, Santa Cruz de Tenerife, Spain.
    (2) Research Unit, Hospital Universitario Nuestra Señora de Candelaria, Ctra. del Rosario 145, 38010, Santa Cruz de Tenerife, Spain.
    (3) Pulmonary Division, Clínica Universitaria de Navarra, Pamplona, Spain.
    (4) Centro de Investigación Médica Aplicada (CIMA), UNAV, Pamplona, Spain.
    (5) Pulmonary and Critical Care Department, Brigham and Women's Hospital, Boston, MA, USA.
    (6) Pulmonary Division, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain. 

    Respiratory Research 13 de ABRIL de 2017

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra